# 🔺 Hypercalcemia

### 🚨 EMERGENCY HYPERCALCEMIA PROTOCOL (Ca++ ≥ 14 mg/dL)

#### ⚡ IMMEDIATE (First Hour)

- Normal saline 200-300 mL/hr
- Calcitonin 4 IU/kg IM/SC q12h
- Monitor cardiac rhythm
- Neuro checks q2h

#### 🏥 WITHIN 4-6 HOURS

- Bisphosphonate (zoledronic acid)
- Continue aggressive hydration
- Furosemide if volume overloaded
- Avoid thiazides and calcium

#### 🔍 WORKUP PRIORITIES

- PTH level (stat)
- PTHrP if PTH suppressed
- 25-OH vitamin D, 1,25-OH vitamin D
- CBC, CMP, phosphorus

⚠️ Calcium \>14 mg/dL is life-threatening - Treat aggressively! ⚠️

### 🎯 CRITICAL: Calcium \>13 mg/dL = High Suspicion for MALIGNANCY

#### 📊 Statistical Reality

- **Ca++ \>13 mg/dL:** 80-90% malignancy
- **Ca++ \>14 mg/dL:** \>95% malignancy
- **Inpatient hypercalcemia:** Malignancy \#1 cause
- **Outpatient hypercalcemia:** Primary hyperparathyroidism \#1

#### 🔬 Immediate Workup

- PTH level (should be suppressed)
- PTHrP (parathyroid hormone-related protein)
- Chest X-ray, CT chest/abdomen/pelvis
- Protein electrophoresis, SPEP/UPEP
- 25-OH and 1,25-OH vitamin D

🚨 Don't delay cancer workup when Ca++ \>13 - Time is critical! 🚨

## 🔍 Diagnostic Approach: PTH-Dependent vs PTH-Independent

### ⚡ PTH-Guided Diagnostic Algorithm

#### 📈 PTH ELEVATED or INAPPROPRIATELY NORMAL

PTH-Dependent Hypercalcemia

- **Primary Hyperparathyroidism (85%):**
  - Adenoma (80-85%)
  - Hyperplasia (10-15%)
  - Carcinoma (\<5%)
- **Tertiary Hyperparathyroidism:** CKD, post-transplant
- **FHH (Familial Hypocalciuric Hypercalcemia):**
  - Check 24h urine calcium
  - Ca/Cr clearance ratio \<0.01
- **Lithium-induced:** Chronic lithium therapy

Next Step: Neck ultrasound, Tc-99m sestamibi scan

#### 📉 PTH SUPPRESSED (\<20 pg/mL)

PTH-Independent Hypercalcemia

- **Malignancy (90% of cases):**
  - PTHrP-mediated (80%)
  - Osteolytic metastases (20%)
  - 1,25(OH)2D production (lymphoma)
- **Granulomatous Diseases:**
  - Sarcoidosis, histoplasmosis
  - Extra-renal 1α-hydroxylase
- **Endocrine:** Thyrotoxicosis, adrenal insufficiency
- **Medications:** Vitamin D, thiazides, calcium

Next Step: PTHrP, imaging for malignancy

## 🩸 Lymphoma-Associated Hypercalcemia: Comprehensive Analysis

### 🎯 Lymphoma Subtypes & Hypercalcemia Risk

#### 🧬 HODGKIN LYMPHOMA

- **Classical Subtypes:** Nodular sclerosis (most common)
- **Hypercalcemia Incidence:** 10-15% of cases
- **Reed-Sternberg Cells:** Express CD30, CD15
- **Cytokines:** IL-1, TNF-α, IL-6 production
- **Age Groups:** Bimodal distribution (20s, \>55y)
- **B-symptoms:** Fever, night sweats, weight loss
- **Staging:** Often localized at presentation

#### 🧬 NON-HODGKIN LYMPHOMA

- **High-Risk Subtypes:** DLBCL, Burkitt, PTCL
- **B-cell Lymphomas:** 85% of NHL cases
- **Hypercalcemia Rate:** 5-20% depending on subtype
- **Extra-nodal Disease:** 40% have extra-nodal involvement
- **Aggressive Course:** Rapidly progressive
- **CNS Involvement:** Higher risk in aggressive subtypes
- **Bone Marrow:** Frequent involvement

#### 🩸 ADULT T-CELL LEUKEMIA/LYMPHOMA (ATLL)

- **HTLV-1 Associated:** Retroviral oncogenesis
- **Hypercalcemia Rate:** 50-70% of acute/lymphoma types
- **Geographic Distribution:** Japan, Caribbean, South America
- **Clinical Subtypes:** Acute, lymphoma, chronic, smoldering
- **PTHrP Production:** Common mechanism
- **Skin Lesions:** Characteristic feature (70%)
- **Prognosis:** Poor (median survival 6-10 months)

#### 🧬 BURKITT LYMPHOMA

- **MYC Translocation:** t(8;14), t(2;8), t(8;22)
- **Hypercalcemia Rate:** 10-25% of cases
- **Variants:** Endemic (Africa), sporadic, immunodeficiency
- **Rapid Growth:** Doubling time 24-48 hours
- **EBV Association:** Strong in endemic variant
- **Tumor Lysis Risk:** Very high with treatment
- **CNS Involvement:** 15-20% at presentation

#### 🔬 Mechanism: Extra-Renal 1α-Hydroxylase in Lymphomas

##### Cellular Source

- **Tumor-Associated Macrophages:** M2 phenotype activation
- **Lymphoma Cells:** Direct 1α-hydroxylase expression
- **Cytokine Milieu:** IFN-γ, TNF-α, IL-2 upregulation
- **CYP27B1 Gene:** Upregulated in tumor microenvironment

##### Biochemical Pattern

- **25(OH)D:** Normal or low (substrate consumption)
- **1,25(OH)2D:** Markedly elevated (\>100 pg/mL)
- **PTH:** Appropriately suppressed (\<10 pg/mL)
- **FGF23:** May be elevated as compensatory response

### 📊 Clinical Presentation & Diagnostic Workup

#### 🎯 Clinical Features

- **Constitutional Symptoms:** B-symptoms in 30-50%
- **Lymphadenopathy:** Mediastinal, abdominal, peripheral
- **Organomegaly:** Splenomegaly (40%), hepatomegaly (30%)
- **Hypercalcemia Symptoms:** Often early presentation
- **Performance Status:** Often decreased at presentation
- **Age Distribution:** Variable by subtype

#### 🔬 Laboratory Workup

- **Complete Metabolic Panel:** Calcium, phosphorus, renal function
- **PTH:** Suppressed (\<20 pg/mL)
- **25(OH)D & 1,25(OH)2D:** Elevated 1,25 diagnostic
- **Lactate Dehydrogenase:** Often markedly elevated
- **Uric Acid:** May be elevated (tumor burden)
- **Flow Cytometry:** Blood and bone marrow

#### 📷 Imaging Studies

- **CT Chest/Abdomen/Pelvis:** Staging assessment
- **PET-CT:** Gold standard for staging lymphoma
- **Brain MRI:** If CNS symptoms or high-risk histology
- **Bone Marrow Biopsy:** Staging for most subtypes
- **Tissue Biopsy:** Core needle or excisional
- **Lumbar Puncture:** High-risk cases (Burkitt, DLBCL)

#### ⚗️ Molecular/Genetic Testing

- **Immunohistochemistry:** CD20, CD30, CD15, etc.
- **Flow Cytometry:** Surface markers, clonality
- **Cytogenetics:** Chromosomal translocations
- **FISH Studies:** MYC, BCL2, BCL6 rearrangements
- **NGS Panels:** Mutation analysis for prognosis
- **HTLV-1 Testing:** If T-cell lymphoma suspected

### 📊 Treatment Approach: Lymphoma-Associated Hypercalcemia

#### 🚑 EMERGENCY MANAGEMENT

- **Hydration:** NS 200-300 mL/hr immediately
- **Glucocorticoids:** Prednisone 40-60 mg daily (first-line)
- **Calcitonin:** 4 IU/kg q12h (rapid effect)
- **Bisphosphonates:** Zoledronic acid 4mg IV
- **Monitor Closely:** Tumor lysis syndrome risk
- **Dialysis:** If severe hypercalcemia + renal failure

#### 💊 STEROID THERAPY (PREFERRED)

- **Mechanism:** Suppresses extra-renal 1α-hydroxylase
- **Dosing:** Prednisone 40-60 mg daily
- **Response Time:** 24-72 hours typically
- **Dual Benefit:** Treats lymphoma AND hypercalcemia
- **Monitoring:** Blood glucose, infections
- **Duration:** Continue until chemotherapy initiated

#### 🧬 LYMPHOMA-SPECIFIC THERAPY

- **Hodgkin:** ABVD, BEACOPP regimens
- **DLBCL:** R-CHOP or R-EPOCH
- **Burkitt:** Intensive regimens (R-CODOX-M/IVAC)
- **ATLL:** Combination therapy, often poor response
- **Timing:** Start within 48-72 hours if possible
- **TLS Prophylaxis:** Allopurinol, hydration, rasburicase

#### 🚨 COMPLICATIONS & MONITORING

- **Tumor Lysis Syndrome:** High risk with treatment
- **Renal Failure:** From hypercalcemia or TLS
- **CNS Involvement:** Requires intrathecal therapy
- **Hypercalcemic Crisis:** Neurologic emergency
- **Response Monitoring:** Daily calcium, phosphorus
- **Long-term:** May need vitamin D supplementation

#### ⚠️ CRITICAL PEARLS: Lymphoma Hypercalcemia

- 🔴 **Glucocorticoids are FIRST-LINE therapy** (unlike other hypercalcemia)
- 🔴 **Dual mechanism:** Treats both lymphoma and hypercalcemia
- 🔴 **1,25(OH)2D elevation** is diagnostic hallmark

&nbsp;

- 🔴 **High TLS risk:** Prevent with allopurinol/rasburicase
- 🔴 **Rapid progression:** Don't delay systemic therapy
- 🔴 **Poor prognosis:** Especially with hypercalcemia at presentation

## 🔤 VITAMINS TRAP: Complete Hypercalcemia Differential

### 📚 VITAMINS TRAP: Comprehensive Hypercalcemia Mnemonic

#### 🆅 - VITAMIN D INTOXICATION

- **Excessive Supplementation:** \>50,000 IU daily
- **25(OH)D Level:** \>100 ng/mL (toxicity)
- **1,25(OH)2D:** Elevated (conversion overload)
- **Mechanism:** ↑ intestinal Ca absorption
- **Treatment:** Stop vitamin D, glucocorticoids

#### 🅸 - IMMOBILIZATION

- **Paget's Disease:** Especially with immobilization
- **Young Patients:** Spinal cord injury, fractures
- **Bone Turnover:** ↑ resorption vs formation
- **Time Course:** Weeks to months of bedrest
- **Treatment:** Early mobilization, bisphosphonates

#### 🅣 - THIAZIDE DIURETICS

- **Prevalence:** 8-10% of patients
- **Mechanism:** ↑ distal Ca reabsorption
- **Unmasking:** May reveal hyperparathyroidism
- **Reversible:** Usually within days of stopping
- **Testing:** Stop drug, recheck in 2-4 weeks

#### 🅰 - VITAMIN A INTOXICATION

- **Chronic Toxicity:** \>25,000 IU daily for months
- **Acute Toxicity:** \>300,000 IU single dose
- **Symptoms:** Hepatotoxicity, bone pain
- **Mechanism:** ↑ bone resorption
- **Diagnosis:** Elevated retinol levels

#### 🅼 - MALIGNANCY

- **PTHrP (80%):** Squamous cell, lung, H&N;, RCC
- **Osteolytic (20%):** Breast, multiple myeloma
- **Lymphomas:** Extra-renal 1α-hydroxylase
- **Ca++ \>13 mg/dL:** 80-90% malignancy
- **Prognosis:** Median survival 2-3 months

#### 🅸 - INTOXICATIONS

- **Milk-Alkali Syndrome:** Ca + absorbable alkali
- **Aluminum Hydroxide:** With Ca supplements
- **Theophylline:** Overdose (rare)
- **Calcium Supplements:** Excessive intake
- **Lithium:** Affects CaSR, ↑ PTH

#### 🅽 - NEOPLASM (LYMPHOMAS)

- **Hodgkin Lymphoma:** Classical subtype
- **Non-Hodgkin:** B-cell lymphomas
- **ATLL:** HTLV-1 associated T-cell
- **Mechanism:** Macrophage 1α-hydroxylase
- **1,25(OH)2D:** Markedly elevated

#### 🆂 - SARCOIDOSIS & GRANULOMAS

- **Sarcoidosis:** 10-20% develop hypercalcemia
- **Histoplasmosis:** Ohio/Mississippi valleys
- **Tuberculosis:** Miliary TB especially
- **Coccidioidomycosis:** Southwest US
- **Treatment:** Glucocorticoids first-line

#### 🅣 - THYROTOXICOSIS

- **Prevalence:** 20% of hyperthyroid patients
- **Mechanism:** ↑ bone resorption via osteoclasts
- **T3/T4 Effects:** Direct bone effects
- **Reversible:** With treatment of hyperthyroidism
- **Mild:** Usually Ca \<12 mg/dL

#### 🆁 - RENAL FAILURE

- **Tertiary HPT:** Autonomous parathyroid glands
- **Post-Transplant:** 30-50% develop hypercalcemia
- **Aluminum Toxicity:** In dialysis patients
- **Recovery Phase:** AKI with bone remineralization
- **Treatment:** Cinacalcet, parathyroidectomy

#### 🅰 - ADRENAL INSUFFICIENCY

- **Addison's Disease:** Primary adrenal failure
- **Mechanism:** Volume depletion, ↓ renal excretion
- **Associated:** Hyperkalemia, hyponatremia
- **Diagnosis:** Cortisol stimulation test
- **Treatment:** Glucocorticoid replacement

#### 🅿 - PRIMARY HYPERPARATHYROIDISM

- **Adenoma (85%):** Single gland disease
- **Hyperplasia (15%):** Multiple glands
- **Carcinoma (\<1%):** Very rare
- **PTH:** Elevated or inappropriately normal
- **Treatment:** Parathyroidectomy (cure \>95%)

#### 🎯 VITAMINS TRAP Clinical Application

##### PTH-Independent Causes (PTH \<20)

- **V**itamin D, **V**itamin A
- **M**alignancy (most common)
- **I**ntoxications
- **N**eoplasm (lymphomas)
- **S**arcoidosis & granulomas
- **T**hyrotoxicosis
- **A**drenal insufficiency

##### PTH-Dependent Causes (PTH ≥20)

- **P**rimary hyperparathyroidism
- **R**enal failure (tertiary HPT)
- **T**hiazide diuretics (unmasking)
- **I**mmobilization (with hyperparathyroidism)
- FHH (Familial Hypocalciuric Hypercalcemia)
- Lithium-induced hyperparathyroidism

## 🔬 Comprehensive Laboratory Differential Diagnosis

### 📊 Hypercalcemia Laboratory Patterns by Etiology

Complete diagnostic framework for identifying the underlying cause of hypercalcemia

| ETIOLOGY | PTH | PTHrP | 1,25(OH)₂D | 25(OH)D | Phosphate | Other Key Labs |
|----|----|----|----|----|----|----|
| PRIMARY HYPERPARATHYROIDISM | ↑↑ | Normal | ↑ or normal | Normal | ↓ | ALP ↑, 24h UCa ↑ |
| MALIGNANCY - PTHrP-mediated | ↓ | ↑↑ | ↓ or normal | Normal | ↓ | ALP ↑, SPEP abnormal |
| MALIGNANCY - Local osteolytic | ↓ | Normal | ↓ or normal | Normal | Normal/↑ | ALP ↑, imaging shows lesions |
| MALIGNANCY - Lymphoma | ↓ | Normal | ↑↑ | Normal/↑ | Normal/↑ | LDH ↑, lymphadenopathy |
| VITAMIN D INTOXICATION | ↓ | Normal | ↑ | ↑↑ | Normal/↑ | History of supplements |
| VITAMIN A INTOXICATION | ↓ | Normal | Normal | Normal | Normal | Vitamin A level ↑↑ |
| IMMOBILIZATION | ↓ | Normal | ↓ or normal | Normal | Normal/↑ | ↑ bone resorption markers |
| THIAZIDES | ↑ or normal | Normal | Normal | Normal | Normal | Recent thiazide use |
| THYROTOXICOSIS | ↓ | Normal | Normal | Normal | Normal/↑ | TSH ↓, T4 ↑, T3 ↑ |
| ADDISON'S DISEASE | Normal/↑ | Normal | Normal | Normal | Normal | Cortisol ↓, ACTH ↑ |
| MILK-ALKALI SYNDROME | ↓ | Normal | Normal | Normal | Normal/↑ | Metabolic alkalosis, ↑ Ca intake |
| SARCOIDOSIS | ↓ | Normal | ↑↑ | Normal/↓ | Normal/↑ | ACE ↑, chest imaging |
| GRANULOMATOUS DISEASES | ↓ | Normal | ↑↑ | Normal | Normal/↑ | 1α-hydroxylase activity |
| WILLIAMS SYNDROME | ↓ | Normal | ↑ | Normal | Normal | Characteristic facies |
| RENAL FAILURE (Tertiary HPT) | ↑↑ | Normal | Low/normal | Normal | ↑↑ | CrCl \<30, long-standing CKD |
| ADRENAL INSUFFICIENCY | Normal/↑ | Normal | Normal | Normal | Normal | Morning cortisol \<3 μg/dL |

#### 🔑 Key Interpretation Guidelines

##### PTH Patterns

- **↑↑ Elevated:** Primary hyperparathyroidism, tertiary HPT
- **↑ or N (inappropriately normal):** May unmask mild primary HPT
- **↓ Suppressed (\<20 pg/mL):** PTH-independent causes

##### Vitamin D Patterns

- **↑↑ 1,25(OH)₂D:** Granulomas, lymphoma (extra-renal production)
- **↑↑ 25(OH)D:** Vitamin D intoxication (\>100 ng/mL)
- **Both normal:** Most other causes of hypercalcemia

##### Phosphate Patterns

- **↓ Low:** PTH or PTHrP effect (phosphaturia)
- **↑↑ High:** Renal failure, tumor lysis
- **Normal/variable:** Most other etiologies

## 🧬 PTHrP-Mediated Malignancy: Specific Cancer Types

### 🎯 Malignancies That Cause PTHrP Elevation

**PTHrP (Parathyroid Hormone-Related Protein):** Mimics PTH action, causing calcium reabsorption and phosphate wasting

#### 🫁 Lung Cancers (40% of PTHrP)

- **Squamous Cell:** Most common overall
- **Large Cell:** High PTHrP production
- **Adenocarcinoma:** Less common but possible
- **Small Cell:** Rarely causes PTHrP

#### 🦴 Head & Neck Cancers (20%)

- **Squamous Cell:** Oral, laryngeal, pharyngeal
- **Salivary Gland:** Adenoid cystic carcinoma
- **Thyroid:** Anaplastic, medullary (rare)

#### 🏥 Genitourinary Cancers (15%)

- **Renal Cell Carcinoma:** Clear cell type
- **Bladder Cancer:** Squamous and transitional
- **Ovarian:** Clear cell, squamous
- **Cervical:** Squamous cell carcinoma

#### 🔬 Other Malignancies (25%)

- **Breast Cancer:** Especially with bone mets
- **Esophageal:** Squamous cell type
- **Skin:** Squamous cell carcinoma
- **Neuroendocrine:** Pancreatic islet cell

#### 🧪 PTHrP vs PTH Laboratory Differentiation

##### PTHrP-Mediated (Malignancy)

- PTH: Suppressed (\<20 pg/mL)
- PTHrP: Elevated (\>4.2 pmol/L)
- Phosphorus: Low (PTHrP mimics PTH)
- 1,25(OH)2D: Low or normal
- Alkaline phosphatase: Often elevated

##### Primary Hyperparathyroidism

- PTH: Elevated or inappropriately normal
- PTHrP: Normal (\<4.2 pmol/L)
- Phosphorus: Low
- 1,25(OH)2D: High or high-normal
- 24h urine calcium: Elevated

## 🌿 Granulomatous Diseases & Lymphoma: Vitamin D Pathway

### 🔬 Extra-Renal 1α-Hydroxylase Activity

**Mechanism:** Activated macrophages and granuloma cells produce 1α-hydroxylase, converting 25(OH)D to active 1,25(OH)2D

#### 🫁 Sarcoidosis (Most Common)

- 10-20% develop hypercalcemia
- 50% have hypercalciuria
- More common in summer (sun exposure)
- Bilateral hilar lymphadenopathy on CXR
- ACE level often elevated

#### 🦠 Infectious Granulomas

- **Histoplasmosis:** Ohio/Mississippi valleys
- **Coccidioidomycosis:** Southwest US
- **Tuberculosis:** Especially miliary TB
- **Blastomycosis:** Great Lakes region

#### 🩸 Lymphomas & Hematologic Malignancies

- **Hodgkin Lymphoma:** Classical nodular sclerosis subtype
- **Aggressive B-cell NHL:** DLBCL, Burkitt lymphoma
- **Adult T-cell Leukemia/Lymphoma:** HTLV-1 associated
- **Plasmacytoma:** Extra-medullary plasma cell tumor
- **Prevalence:** 10-25% of lymphoma patients
- **Extra-nodal sites:** GI, CNS, bone marrow

#### 🧪 Laboratory Pattern

- PTH: Suppressed
- 25(OH)D: Normal or low
- **1,25(OH)2D: ELEVATED** (key finding)
- Hypercalciuria prominent
- Nephrolithiasis common

#### 💊 Treatment of Granulomatous Hypercalcemia

##### First-Line Therapy

- **Corticosteroids:** Prednisone 20-40 mg daily
- **Mechanism:** Suppresses 1α-hydroxylase
- **Response:** Usually within 7-10 days
- **Duration:** Taper slowly over weeks

##### Adjunct Measures

- Avoid sun exposure and vitamin D
- Low calcium diet (800-1000 mg/day)
- Treat underlying infection if present
- Monitor for steroid side effects

## 🦴 Clinical Manifestations: "Stones, Bones, Groans, and Psychiatric Moans"

### 🎯 Classic Symptom Complex by Calcium Level

#### 🗿 STONES (Nephrolithiasis)

- **Kidney Stones (20-30%):** Calcium oxalate/phosphate
- **Nephrocalcinosis:** Calcium deposition in tubules
- **Polyuria/Polydipsia:** Nephrogenic diabetes insipidus
- **Progressive CKD:** From chronic hypercalciuria
- **Mechanism:** ↑ calcium excretion, ↓ concentrating ability

Occurs at Ca++ \>11.5 mg/dL

#### 🦴 BONES (Skeletal Effects)

- **Osteoporosis:** Especially in hyperparathyroidism
- **Osteitis Fibrosa Cystica:** "Brown tumors"
- **Pathologic Fractures:** Vertebral, hip, wrist
- **Bone Pain:** Generalized aching
- **Joint Stiffness:** Morning stiffness

Long-term consequence of chronic elevation

#### 😫 GROANS (Gastrointestinal)

- **Nausea and Vomiting:** Common early symptom
- **Constipation:** Decreased bowel motility
- **Abdominal Pain:** Cramping, peptic ulcer disease
- **Anorexia:** Loss of appetite, weight loss
- **Ileus:** Severe hypercalcemia (\>14 mg/dL)

Occurs at Ca++ \>12 mg/dL

#### 🧠 PSYCHIATRIC MOANS (Neuropsychiatric)

- **Depression:** Most common psychiatric symptom
- **Cognitive Impairment:** Memory loss, confusion
- **Psychosis:** Paranoia, hallucinations
- **Personality Changes:** Irritability, apathy
- **Coma:** Severe hypercalcemia (\>15 mg/dL)

Can occur with mild elevation

#### ⚠️ SEVERE HYPERCALCEMIA MANIFESTATIONS (Ca++ ≥14 mg/dL)

##### 💓 Cardiac

- QT shortening
- Arrhythmias
- AV blocks
- Cardiac arrest

##### 🧠 Neurologic

- Stupor/coma
- Seizures
- Muscle weakness
- Hyporeflexia

##### 🏥 Other

- Acute kidney injury
- Severe dehydration
- Hypercalcemic crisis
- Death (untreated)

## 💧 Hypercalcemia-Induced Nephrogenic Diabetes Insipidus

### 🎯 Mechanism: How Hypercalcemia Causes Nephrogenic DI

#### 🔬 Cellular Mechanisms

1.  **Aquaporin-2 (AQP2) Downregulation:**
    - Hypercalcemia reduces AQP2 expression
    - Decreased water channel insertion
    - Impaired water reabsorption
2.  **ADH Receptor Dysfunction:**
    - Calcium interferes with V2 receptor
    - Disrupted cAMP signaling
    - Reduced ADH responsiveness
3.  **Medullary Damage:**
    - Calcium deposition (nephrocalcinosis)
    - Chronic tubulointerstitial nephritis
    - Loss of concentrating gradient

#### 📊 Clinical Threshold & Presentation

- **Threshold:** Ca++ \>11.5 mg/dL consistently
- **Polyuria:** \>3L/day urine output
- **Polydipsia:** Compensatory increased thirst
- **Urine Osmolality:** \<300 mOsm/kg (inappropriately dilute)
- **Dehydration Risk:** If water access limited
- **Hypernatremia:** Common complication

##### ⚠️ Key Clinical Point

**Reversibility:** NDI usually reverses within days to weeks after calcium normalization, but chronic cases may have permanent damage

#### 💊 Treatment Strategy for Hypercalcemic NDI

##### 🎯 Primary Goal

- **Normalize Calcium:** Treat underlying cause
- **Aggressive Hydration:** NS 200-300 mL/hr
- **Bisphosphonates:** Zoledronic acid 4mg IV
- **Calcitonin:** 4 IU/kg q12h (rapid onset)

##### 💧 NDI-Specific Measures

- **Free Water Access:** Ensure adequate intake
- **Thiazide Diuretics:** May help concentration
- **Amiloride:** If lithium co-factor
- **Monitor Closely:** Na+, urine output, volume status

## 💊 Comprehensive Treatment Protocol

1 **IMMEDIATE HYDRATION (First-Line):** Normal Saline 200-300 mL/hr\
• Goal: Restore intravascular volume, increase calcium excretion • Monitor for volume overload • Continue until volume replete 2 **FORCED DIURESIS (After Volume Restoration):** Furosemide 20-40 mg IV q6-8h\
• ONLY after adequate hydration • Increases calcium excretion • Replace losses with 0.45% saline • Monitor electrolytes closely 3 **CALCITONIN (Rapid Onset):** 4 IU/kg IM/SC every 12 hours\
• Onset: 2-4 hours • Peak effect: 4-6 hours • Duration: 6-8 hours • TEMPORARY effect (tachyphylaxis in 48-72h)

#### 💀 BISPHOSPHONATES: Definitive Long-Term Therapy

##### 🥇 First-Line: Zoledronic Acid

- **Dose:** 4 mg IV over 15-30 minutes
- **Onset:** 24-48 hours
- **Peak:** 4-7 days
- **Duration:** 2-4 weeks
- **Efficacy:** Most potent available

##### 🥈 Alternative: Pamidronate

- **Dose:** 60-90 mg IV over 2-4 hours
- **Onset:** 24-72 hours
- **Peak:** 5-7 days
- **Duration:** 1-3 weeks
- **Use:** If zoledronic acid unavailable

##### ⚠️ BISPHOSPHONATE CONTRAINDICATIONS & WARNINGS

###### Absolute Contraindications

- Severe renal impairment (CrCl \<30)
- Hypocalcemia
- Pregnancy/breastfeeding
- Known hypersensitivity

###### Monitoring & Precautions

- Pre-infusion: CBC, CMP, Ca, Phos, Mg
- Dental exam before long-term use
- Monitor for osteonecrosis of jaw
- Atypical fracture risk (rare)

4 **ADDITIONAL THERAPIES (Refractory Cases):** Based on underlying etiology\
• Corticosteroids for granulomatous disease (prednisone 20-40 mg daily) • Dialysis for severe cases with renal failure • Cinacalcet for hyperparathyroidism • Gallium nitrate (rare use)

## 🧮 Interactive Hypercalcemia Calculator

### Comprehensive Diagnostic & Treatment Calculator

Serum Calcium (mg/dL): 12.5 Albumin (g/dL): 4.0 PTH (pg/mL): 25 Age (years): 65 Clinical Setting: Symptoms Present: Urine Output: Cancer History: Calculating comprehensive diagnostic and treatment plan...

## 📋 Key Learning Points Summary

### 🎯 Essential Clinical Pearls

#### 🔍 Diagnostic Priorities

- Ca++ \>13 mg/dL = 80-90% malignancy
- PTH guides workup: elevated vs suppressed
- PTHrP elevated in 80% of malignancy cases
- 1,25(OH)2D elevated in granulomatous disease

#### 💊 Treatment Essentials

- Hydration first: NS 200-300 mL/hr
- Calcitonin rapid but temporary (tachyphylaxis)
- Bisphosphonates definitive therapy
- Furosemide only AFTER volume restoration

#### ⚠️ Critical Complications

- Nephrogenic DI at Ca++ \>11.5 mg/dL
- Cardiac arrhythmias, QT shortening
- Nephrocalcinosis and chronic kidney disease
- Hypercalcemic crisis at Ca++ ≥14 mg/dL

### Also on this topic

The same subject at other levels of depth.

- **Clinical Mastery deep dive:** [Hypercalcemia Review Complete](https://urinenephrology.org/mastery/electrolytes-advanced/hypercalcemia-review.html)
- **Student handout:** [Hypercalcemia: Student Handout](https://urinenephrology.org/student-resources/electrolyte-acid-base/hypercalcemia-student-handout.html)


---

[Website version](https://urinenephrology.org/2025_UDPA_Lectures_Live/electrolytes/calcium/hypercalcemia.html) · Markdown synchronized October 3, 2026.